Drug Trial Radar · NCT03498716
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,199
Actual
Start
Aug 2, 2018
Primary completion
Aug 14, 2023
Study completion Aug 14, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Breast International Group; Alliance Foundation Trials, LLC.; Jules Bordet Institute; Frontier Science & Technology Research Foundation, Inc.
- First posted
- Apr 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Conditions
- Triple Negative Breast Cancer
Interventions
AtezolizumabDrug
Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses. Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year
PaclitaxelDrug
Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
Dose-dense Doxorubicin or dose-dense EpirubicinDrug
Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses. Or Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses
CyclophosphamideDrug
Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (iDFS)Time frame: From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)
Locations
364 sites in 31 countries. Site status is shown where the registry gives one.
John Muir Health Clinical Research Center
Concord, California
Cedars-Sinai Medical Center
Los Angeles, California
Martin-O?Neil Cancer Center
St. Helena, California
Baptist - MD Anderson Cancer Center
Jacksonville, Florida
Advocate Illinois Masonic Outpatient Center for Advanced Care
Chicago, Illinois
Des Moines Oncology Research Association
Des Moines, Iowa
Cancer Center of Kansas
Wichita, Kansas
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Fairview Southdale Medical Oncology Clinic
Edina, Minnesota
HCA Midwest Division
Kansas City, Missouri
New Hampshire Hematology Oncology
Manchester, New Hampshire
Monter Cancer Center
Lake Success, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Rochester General Hospital; Lipson Cancer and Blood Center
Rochester, New York
SCRI
Nashville, Tennessee
Intermountain Precision Genomics Cancer Research Clinic-Dixie
St. George, Utah
St. Mary's Medical Center
Huntington, West Virginia
Centro de Oncologia e; Investigacion Buenos Aires - COIBA
Berazategui, Argentina
INSTITUTO DE INVESTIGACIONES METABOLICAS (IDIM); Oncology
Ciudad Autonoma Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Clinica Universitaria Reina Fabiola
Córdoba, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Instituto de Oncología de Rosario
Rosario, Argentina
Centro Medico San Roque
San Miguel de Tucumán, Argentina
Fundación Ars Medica
San Salvador de Jujuy, Argentina
Centro de Investigacion Clinica - Clinica Viedma S.A.; Oncology Department
Viedma, Argentina
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Lismore Base Hospital
Lismore, New South Wales, Australia
Macquarie University Hospital
Macquarie Park, New South Wales, Australia
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
Icon Cancer Care Wesley
Auchenflower, Queensland, Australia
Icon Cancer Foundation; Icon Cancer Care Chermside
Chermside, Queensland, Australia
Icon Cancer Care South Brisbane
South Brisbane, Queensland, Australia
Mater Hospital; Cancer Services
South Brisbane, Queensland, Australia
Icon Cancer Foundation; Icon Cancer Care Southport
Southport, Queensland, Australia
Princess Alexandra Hospital; Cancer Trials Unit
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital; Cancer Centre
Adelaide, South Australia, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Austin Hospital Olivia Newton John Cancer Centre
Heidelberg, Victoria, Australia
Showing 40 of 364 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.